Dr. Haidar is the Executive Director of the Dr. Moise Khayrallah Pharmaceutical and Medical Research Center (PMRC). Prior to this appointment, Dr. Haidar served 27 years in different roles within the US FDA, Center for Drug Evaluation and Research. These included Senior Science Advisor, Office of Study Integrity and Surveillance; Branch Chief; Deputy Director, and Acting Director for the Division of Generic Drugs Bioequivalence (BE) Evaluation. Dr. Haidar has served as Project Officer for FDA-funded research projects impacting policies and recommendations to industry and other stakeholders. Examples include Highly Variable Drugs: Scaled Average Bioequivalence; Impact of Excipients on BE of BCS Class 3 Drugs; and early use of artificial neural networks (machine learning) in Pharmacokinetics and Pharmacodynamics modeling. His research activities and collaborations produced over 40 publications and a book chapter. Additionally, Dr. Haidar represented FDA in numerous national and international conferences; joint international inspections with the European Medicines Agency (EMA) and the World Health Organization (WHO). He was also selected for a scientist-exchange program with the Medical Products Agency in Uppsala, Sweden.